Evidence map›Paper›PMID 28971376›Full record

ArticleJournal of neurovirology2017

Association of age and time of disease with HIV-associated neurocognitive disorders: a Japanese nationwide multicenter study.

Ei Kinai, Kensuke Komatsu, Maiko Sakamoto, Toshibumi Taniguchi, Aya Nakao, Hidetoshi Igari, Kiyonori Takada, Aki Watanabe, Ai Takahashi-Nakazato, Misao Takano and 3 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of neurovirology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ei KinaiAIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan. ekinai@acc.ncgm.go.jp.ORCID http://orcid.org/0000-0001-5415-0854
Kensuke KomatsuAIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Maiko SakamotoCenter for Comprehensive Community Medicine, Saga University, Saga, Japan.
Toshibumi TaniguchiDepartment of Infectious Diseases, Chiba University, Chiba, Japan.
Aya NakaoDepartment of Infectious Diseases, Ehime University, Matsuyama, Japan.
Hidetoshi IgariDepartment of Infectious Diseases, Chiba University, Chiba, Japan.
Kiyonori TakadaDepartment of Infectious Diseases, Ehime University, Matsuyama, Japan.
Aki WatanabeAIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Ai Takahashi-NakazatoAIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Misao TakanoAIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Yoshimi KikuchiAIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Shinichi OkaAIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
for HIV-Associated Neurocognitive Disorders in Japanese (J-HAND study group)

Funding

National Center for Global Health and Medicine 26-G-102
6 · The paper itself

Abstract

There is no detailed information on the association between age, time of disease, and HIV-associated neurocognitive disorders (HAND). In this prospective study involving 17 medical facilities across Japan, we recruited HIV-infected patients to complete a 14-test neuropsychological battery that assess eight neurocognitive domains. HAND were diagnosed by the Frascati criteria. Of 1399 recruited patients, 728 were enrolled. The prevalence of HAND was 25.3% [13.5% asymptomatic neurocognitive impairment, 10.6% mild neurocognitive disorder (MND), and 1.2% HIV-associated dementia (HAD)]. Tests that assess executive and visuospatial functions showed better diagnostic accuracy than other tests for HAND. Multivariate analysis identified age (≥ 50 years) and incomplete virological suppression as risk factors for MND and HAD and current ART as a protective factor. The prevalence of MND and HAD was low in the early stage of infection (6.3% in ≥ 2 to < 6 years), then increased in the later stage [17.3% in ≥ 11 years, p = 0.001 (vs. ≥ 2 to < 6 years)], independent of age or treatment. Older patients were more likely to show MND or HAD in the early stage of HIV infection (26.7 vs. 8.7% for < 2 years and 17.4 vs. 3.1% for ≥ 2 to < 6 years, p = 0.040 and 0.004, respectively) compared to younger ones. In conclusion, MND and HAD were more commonly found in later years since diagnosis of HIV infection and older patients are at risk of neurocognitive impairment at the early stage of HIV infection. Tests for executive and visuospatial functions seem more sensitive than other tests for diagnosing HAND.

Indexed as

AdultAge FactorsAIDS Dementia ComplexAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveFemaleHumansJapanMaleMiddle AgedMultivariate AnalysisNeuropsychological TestsPrevalenceProspective StudiesRisk FactorsTime FactorsAnti-HIV AgentsAgeAntiretroviral therapyHIV-associated neurocognitive disordersTime of disease

Identifiers

PMID28971376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.